Big Pharmaโs China Deal Spree Deepens as Latest Tie-Up Could Reach $7.8 Billion
Western drugmakers are accelerating their search for innovation in China as the industry braces for a wave of patent expirations that threatens future revenue. The latest deal, potentially worth up to $7.8 billion, underscores how Chinese biotech has become a critical source of early-stage assets for global pharma giants.
